Immunarray
Immunarray
Agent28Agent Readiness: 28/100. Bottom 25%. Measured by StartupHub.ai. Median 41.ImmunArray develops and markets novel multi-analyte blood-based tests for complex immune-mediated diseases using its iCHIP microarray platform.
About
ImmunArray is a biotechnology company focused on the development and commercialization of advanced diagnostic tools for autoimmune and neurological disorders. Their proprietary iCHIP microarray platform enables the detection of multiple biomarkers from a single blood sample, aiming to improve diagnosis and management of complex immune-mediated diseases.
Key facts
At-a-glance profile data
- Website
- immunarray.com
- Headquarters
- Richmond, United States
- Founded
- 2006
- Total funding
- $10M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 12 Jul 2016 | Series A | $10M | - |
Tech stack
Detected on immunarray.com, last scanned 26 Jun 2026. Run your own scan
- Email provider
- Google Workspace
Add first review
Frequently asked
How much funding has Immunarray raised?
Immunarray has raised a total of $10M in funding. The most recent round on record is Series A.
What is Immunarray's current status?
Immunarray's current operating status is: Inactive.